Table 1.
PPARγ agonist | PPARγ | Tumor type | Molecular mediator(s) of apoptosis | Reference |
---|---|---|---|---|
15d-PGJ2 | Independent | Breast | Unknown | [8] |
Troglitazone and 15d-PGJ2 | Dependent | Thyroid | c-myc | [9] |
Ciglitazone | Dependent | Thyroid | PPARγ | [10] |
Rosiglitazone | Dependent | Thyroid | NF-κB, cyclinD1, caspase-3 | [11] |
Troglitazone and 15d-PGJ2 | Unknown | Colon | c-myc, c-jun, GADD153 | [12] |
Troglitazone | Dependent | Lung | GADD153 | [13] |
Troglitazone | Independent | Colon | EGR-1, NAG-1 | [14, 15] |
15d-PGJ2 | Dependent | Colon | EGR-1, NAG-1 | [15] |
Troglitazone | Dependent | Lung | ERK1/2 | [16] |
Troglitazone | Dependent and independent | Colon | p53, POX | [17] |
Troglitazone | Independent | Prostate | Bcl-2, Bcl-XL | [18] |
15d-PGJ2 | Independent | Oral | Stat3 | [19] |
15d-PGJ2 | Independent | Prostate, bladder | Caspase-3, -7 | [20] |
15d-PGJ2 | Independent | Multiple myeloma, burkitt lymphoma | NF-kappa-B, cIAP-1, XIAP, c-FLIP | [21] |
Rosiglitazone | Dependent | Breast | PPARγ, p53 | [22] |